title: Inhibitor-Immunology-Study. Different HLA-types seem to be involved in the inhibitor development in haemophilia A.
abstract: The development of inhibitors is one of the most important complications of replacement therapy in haemophilia, affecting mortality and morbidity. Inhibitor development is based on complex immunological factors. Cytokines and their receptors, T-cell receptors, and the Major Histocompatibility Complex may play important roles in the development of inhibitors. Earlier studies showed non significant associations between HLA class and inhibitor development. Later studies found an increased risk of inhibitor development if there was a combination between certain factor VIII mutations and HLA antigens. We performed HLA typing in 50 patients with haemophilia A in an effort to find associations with inhibitor development.
  
  
  RESULTS
  25 patients had developed an inhibitor (11 low titre, 14 high titre), and 25 never had. In logistic regression analysis, HLA-A 34, DRB1 0405, DRB1 1301 seemed to be involved in inhibitor development and HLA-A 30, B 13, B15, B 57, Cw 12, DQB1 0303, DPB1 0201 protection against inhibitor development. In our patients, the HLA-associations with inhibitor development were different from those in previous publications.
authors.affiliation: Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover, Germany. wieland.ivonne@mh-hannover.de
authors.forename: I
authors.initials: I
authors.lastname: Wieland
authors.forename: C
authors.initials: C
authors.lastname: Wermes
authors.forename: B
authors.initials: B
authors.lastname: Eifrig
authors.forename: K
authors.initials: K
authors.lastname: Holstein
authors.forename: H
authors.initials: H
authors.lastname: Pollmann
authors.forename: B
authors.initials: B
authors.lastname: Siegmund
authors.forename: C
authors.initials: C
authors.lastname: Bidlingmaier
authors.forename: K
authors.initials: K
authors.lastname: Kurnik
authors.forename: A
authors.initials: A
authors.lastname: Nimtz-Talaska
authors.forename: C
authors.initials: C
authors.lastname: Niekrens
authors.forename: R
authors.initials: R
authors.lastname: Eisert
authors.forename: A
authors.initials: A
authors.lastname: Tiede
authors.forename: C
authors.initials: C
authors.lastname: Ebenebe
authors.forename: M
authors.initials: M
authors.lastname: Lakomek
authors.forename: L
authors.initials: L
authors.lastname: Hoy
authors.forename: K
authors.initials: K
authors.lastname: Welte
authors.forename: K-W
authors.initials: KW
authors.lastname: Sykora
mesh_terms: D005006:Ethnicity; D005169:Factor VIII / Q000235:genetics / Q000276:immunology; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology*; D015234:HLA-A Antigens / Q000235:genetics / Q000276:immunology; D015235:HLA-B Antigens / Q000235:genetics / Q000276:immunology; D006684:HLA-DR Antigens / Q000235:genetics / Q000276:immunology; D059811:HLA-DRB1 Chains; D006467:Hemophilia A / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control; D002836:Hemophilia B / Q000276:immunology / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000235:genetics / Q000276:immunology; D009154:Mutation; D012044:Regression Analysis
chemical_list: D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D007518:Isoantibodies; D005169:Factor VIII